<DOC>
	<DOCNO>NCT00002127</DOCNO>
	<brief_summary>To evaluate safety , antiviral anti-TNF-alpha activity , preliminary efficacy thalidomide reduce weight loss patient HIV waste syndrome .</brief_summary>
	<brief_title>A Phase II , Parallel Group , Randomized , Placebo-Controlled Study Safety Efficacy Thalidomide Reducing Weight Loss Adults With HIV Wasting Syndrome</brief_title>
	<detailed_description>Patients randomize receive either thalidomide 1 2 dos placebo 8 week . Patients respond may continue double-blinded treatment additional 4 week ; nonresponding patient may receive thalidomide 4 week . Per amendment , patient may receive thalidomide 12 week compassionate basis .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>HIV Wasting Syndrome</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Primary prophylaxis opportunistic infection ( AFB blood culture negative ) . Chronic suppressive therapy ( maintenance ) opportunistic infection OTHER THAN Mycobacterium avium Complex ( MAC ) . Patients must : Documented HIV infection . Wasting syndrome . Negative blood PCR acidfast bacteria ( AFB ) negative AFB blood culture within 48 day prior study entry . No active opportunistic infection require systemic therapy within 6 week prior study entry . Life expectancy least 6 week . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Chronic diarrhea ( five unformed stool per day ) . Peripheral neuropathy grade 2 worse . Requirement tube feed intravenous feeding . Any disorder associate moderate severe edema ( e.g. , cirrhosis , nephrosis , congestive heart failure ) . Inability ingest least maintenance diet base present weight . Any condition precludes study participation . Not care primary physician . Concurrent Medication : Excluded : Chronic suppressive therapy ( maintenance ) secondary prophylaxis Mycobacterium avium Complex ( MAC ) ( suppressive therapy opportunistic infection allow ) . Concurrent Treatment : Excluded : Radiotherapy . Patients follow prior condition exclude : Any neoplasm nonmedicated ( i.e. , receive systemic intralesional chemotherapy ) Kaposi 's sarcoma within 1 month prior study entry . Prior intolerance thalidomide . Prior Medication : Excluded : ddC within 1 month prior study entry . Acute systemic therapy opportunistic infection within 6 week prior study entry . Agents anabolic , catabolic , immunomodulatory ( include interferon , megestrol , dronabinol , oxandrolone , growth hormone , systemic corticosteroid , pentoxifylline ) within 30 day prior study entry . Prior Treatment : Excluded : Radiotherapy within 6 week prior study entry . Required ONLY IF patient antiretroviral therapy : Stable regimen AZT ddI least 1 month prior study entry . Active drug abuse within 3 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Thalidomide</keyword>
</DOC>